基于数据挖掘分析ATP1A1基因在肾透明细胞癌中的表达及意义

目的:通过数据挖掘分析ATP1A1在肾透明细胞癌中的表达及意义。方法:通过Oncomine数据库检索关于ATP1A1的mRNA信息,采用The Human Protein Atlas分析ATP1A1蛋白在正常肾组织和肾透明细胞癌中表达情况,GEPIA网站中TCGA数据对ATP1A1低表达的肾透明细胞癌患者进行生存分析,Meth HC数据库分析ATP1A1甲基化水平和蛋白相互作用,利用String-DB数据分析ATP1A1与上下游蛋白的相互作用。结果:肾透明细胞癌(Clear cell Renal Cell Carcinoma,cc RCC)组织中ATP1A1的mRNA表达水平较正常对照组明显降低。免疫组化结果证实ATP1A1蛋白质表达变化与mRNA相似。TCGA数据中得出ATP1A1低表达患者的总体生存期明显短于高表达组患者。此外,ATP1A1基因启动子区在肾透明细胞癌中的甲基化水平明显高于正常肾组织中。同时,ATP1A1与ATP1B1、FXYD2、ATP1B2等蛋白可能存在相互作用。结论:大数据分析结果表明ATP1A1在肾透明细胞癌中低表达,并与其发生发展相关,可能作为其潜在的治疗靶点。

Expression of ATP1A1 Gene in Clear Cell Renal Cell Carcinoma and Its Significance basing on Data Mining

ABSTRACT Objective: To analyze the ATP1A1 expression and its significance in the renal clear cell carcinoma by data mining. Methods: The expression of ATP1A1 protein in normal renal tissue and renal clear cell carcinoma was analyzed by The Human Protein Atlas. Survival analysis of patients with low expression of ATP1A1 in renal clear cell carcinoma using TCGA data from GEPIA website. The ATP1A1 methylation level and protein interaction was analyzed by using the MethHC database, the interaction between ATP1A1 and upstream and downstream proteins was analyzed by String-DB data. Results: The mRNA expression of ATP1A1 in clear cell renal cell carcinoma (ccRCC) was significantly lower than that in the normal control group. The results of immunohistochemistry confirmed that ATP1A1 protein expression was similar to mRNA. The overall survival of patients with low expression of ATP1A1 was significantly lower than the patients with high expression in TCGA data. In addition, it was found that the methylation level of the ATP1A1 gene promoter region in renal clear cell carcinoma was significantly higher than that in normal renal tissue. At the same time, it shows that ATP1A1 interacts with ATP1B1, FXYD2, ATP1B2 and other genes. Conclusion: Based on a large data analysis, ATP1A1 is lowly-expressed in the renal clear cell carcinoma and is related to its development. It may be a potential target for the therapy of ccRCC.